Urinary proteomics and metabolomics studies to monitor bladder health and urological diseases
Published Date:Mar 22 2016
Source:BMC Urol. 16.
Pubmed Central ID:PMC4802825
Funding:1R01DK100974/DK/NIDDK NIH HHS/United States
1U01DK103260/DK/NIDDK NIH HHS/United States
1U01DP006079/DP/NCCDPHP CDC HHS/United States
U24 DK097154/DK/NIDDK NIH HHS/United States
UL1TR000124/TR/NCATS NIH HHS/United States
Assays of molecular biomarkers in urine are non-invasive compared to other body fluids and can be easily repeated. Based on the hypothesis that the secreted markers from the diseased organs may locally release into the body fluid in the vicinity of the injury, urine-based assays have been considered beneficial to monitoring bladder health and urological diseases. The urine proteome is much less complex than the serum and tissues, but nevertheless can contain biomarkers for diagnosis and prognosis of diseases. The urine metabolome has a much higher number and concentration of low-molecular metabolites than the serum or tissues, with a far lower lipid concentration, yet informs directly about dietary and microbial metabolism.
We here discuss the use of mass spectrometry-based proteomics and metabolomics for urine biomarker assays, specifically with respect to the underlying mechanisms that trigger the pathological condition.
Molecular biomarker profiles, based on proteomics and metabolomics studies, reliably distinguish patients from healthy controls, stratify sub-populations with respect to treatment options, and predict therapeutic response of patients with urological disease.
image/gif image/jpeg image/gif image/jpeg image/gif image/jpeg application/octet-stream
You May Also Like: